Coronary Heart Disease

Cardiovascular·MeSH: Coronary Disease

Prevalence

3103.7 / 100K

Incidence

164.9 / 100K/yr

12 drugs in development·5 companies·7 clinical trials

Drug Pipeline by Phase

Approved(4)

Drug	Company
Alginic Sodium Diester Injection	CHINA PHARMA HOLDINGS, INC. (CPHI)
pravastatin	Aptinyx Inc. (APTX)
propylgallate	CHINA PHARMA HOLDINGS, INC. (CPHI)
Propylgallate for Injection	CHINA PHARMA HOLDINGS, INC. (CPHI)

Phase 2(3)

Phase 1(1)

Drug	Company
dfv890	Novartis AG (NVS)

Unknown(2)

Drug	Company
Epi+Gen CHD™	Cardio Diagnostics Holdings Inc. (CDIO)
PrecisionCHD™	Cardio Diagnostics Holdings Inc. (CDIO)

Phase 4(2)

Drug	Company
transdermal nicotine	GH Research PLC (GHRS)
varenicline	GH Research PLC (GHRS)

BioSniper tracks 12 drugs in development for Coronary Heart Disease across 5 companies.

There are 7 clinical trials targeting Coronary Heart Disease tracked by BioSniper.

The estimated prevalence of Coronary Heart Disease is approximately 3103.7 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.